Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +54.12%. A quarter ago, it was expected that this drug developer would post a loss of $0.72 per share when it actually produced a loss of $0.96, delivering a surprise of -33.33%. Over the last four quarters, the company has su ...